GlassScriptPhysician profile
Edward MD Daly
NPI 1801837679
$10,919.57
in general payments reported to CMS, 2019-2025
35 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $1,647 · 2021: $1,523 · 2022: $1,274 · 2023: $3,693 · 2024: $374 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $1,094 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $1,093.98 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,028.81 | 2021-2023 | |
| Pfizer INC. | $940.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $699.51 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $649.45 | 2020-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.26 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $519.46 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $492.29 | 2019-2025 | Myrbetriq, Veozah |
| Novo Nordisk INC | $470.57 | 2019-2021 | |
| Glaxosmithkline, LLC. | $465.92 | 2019-2025 | Trelegy Ellipta, Boostrix, Fluarix Quadrivalent |
| Amgen INC. | $453.52 | 2019-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $444.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $420.30 | 2019-2022 | |
| Abbvie INC. | $359.58 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $341.74 | 2019-2022 | |
| Allergan, INC. | $215.44 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $121.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $108.55 | 2020 | |
| Avanir Pharmaceuticals, INC. | $64.08 | 2019 | |
| Sanofi Pasteur INC. | $58.04 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.27 | 2019-2022 | |
| Tactile Systems Technology INC | $48.43 | 2024 | Entre Plus, Flexitouch Plus |
| Amarin Pharma, INC. | $41.48 | 2019-2020 | |
| Biogen, INC. | $36.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $33.42 | 2023 | Quviviq |
| Dexcom, INC. | $29.19 | 2021 | |
| Biocryst US Sales Co., LLC | $20.45 | 2022 | |
| Csl Behring | $18.36 | 2025 | Andembry |
| Gilead Sciences, INC. | $16.77 | 2020 | |
| Abiomed | $16.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.07 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $14.86 | 2019 | |
| Radius Health, INC. | $13.71 | 2019 | |
| Medtronic, INC. | $12.77 | 2021 | |
| Braintree Laboratories, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.